Pulmonary Vein Isolation Outcomes With Fish Oils

Atrial Fibrillation Clinical Trial

— PUFA  

Official title:

Pulmonary Vein Isolation Outcomes With Eicosapentaenoic Acid (EPA)and Docosahexaenoic Acid (DHA)

Clinical Trial Details — Status: No longer available

Administrative data

• NCT number: NCT00841451
• Other study ID #: 06-123
• Status: No longer available
• Phase: N/A
• First received: February 10, 2009
• Last updated: March 22, 2016

Study information

• Verified date: March 2016
• Source: St. Luke's-Roosevelt Hospital Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Expanded Access

Clinical Trial Summary

Fish oil therapy may decrease the incidence of cardiac arrhythmias. This study will test whether pre-treatment with fish oils before catheter ablation of atrial fibrillation decreases the early post operative occurrence of atrial fibrillation.

Recruitment information / eligibility

• Status: No longer available
• Enrollment: 0
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Paroxysmal Atrial fibrillation (PAF).

• Persistent atrial fibrillation. Persistent AF is not self-limited.

Exclusion Criteria:

• Previous pulmonary vein isolation ablation procedure

• Contraindication for anticoagulation

• Permanent AF

• Severe valvular pathology

• Concurrent use of antiarrhythmic medications

• Inability to give consent

• Pregnancy

Study Design

N/A

Related Conditions & MeSH terms

• Atrial Fibrillation

Intervention

Drug:
• Lovaza (Fish Oils)
Double blinded placebo controlled

Locations

Country	Name	City	State
United States	St.Luke's Hospital 1111 Amsterdam Ave. 3rd Floor Cardiology	New York	New York
United States	University Medical Practice Associates 425 West 59th St. #9C	New York	New York
United States	The Valley Hospital	Ridgewood	New Jersey

Sponsors (2)

Lead Sponsor	Collaborator
St. Luke's-Roosevelt Hospital Center	GlaxoSmithKline

Country where clinical trial is conducted

United States,